Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Kronos Bio Inc (KRON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: KRON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.93% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.30M USD | Price to earnings Ratio - | 1Y Target Price 2.25 |
Price to earnings Ratio - | 1Y Target Price 2.25 | ||
Volume (30-day avg) 169880 | Beta 1.8 | 52 Weeks Range 0.69 - 1.60 | Updated Date 03/30/2025 |
52 Weeks Range 0.69 - 1.60 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.43 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate - | Actual -0.4278 |
Profitability
Profit Margin - | Operating Margin (TTM) -487.36% |
Management Effectiveness
Return on Assets (TTM) -23.48% | Return on Equity (TTM) -69.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -37222399 | Price to Sales(TTM) 5.11 |
Enterprise Value -37222399 | Price to Sales(TTM) 5.11 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.81 | Shares Outstanding 60969200 | Shares Floating 43408251 |
Shares Outstanding 60969200 | Shares Floating 43408251 | ||
Percent Insiders 26.61 | Percent Institutions 32.38 |
Analyst Ratings
Rating 3.5 | Target Price 2.25 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kronos Bio Inc
Company Overview
History and Background
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel cancer therapeutics targeting dysregulated transcription. Founded in 2017, the company focuses on addressing previously undruggable targets.
Core Business Areas
- Drug Discovery and Development: Identifying and developing small molecule therapeutics that modulate the activity of transcription factors and other epigenetic regulators implicated in cancer.
Leadership and Structure
Norbert G. Bischofberger serves as President and CEO. The company has a management team focused on drug discovery, clinical development, and corporate strategy. It operates with a structure common to biopharmaceutical companies, with research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- Entospletinib: A selective spleen tyrosine kinase (SYK) inhibitor being developed for the treatment of acute myeloid leukemia (AML). Currently in clinical trials. Competitors include established treatments for AML like chemotherapy and targeted therapies, as well as other companies developing novel AML treatments.
- KB0742: An oral selective inhibitor of histone deacetylase 3 (HDAC3) designed to mimic the action of early growth response factor 1 (EGR1), is in clinical development, and targets MYC-driven cancers.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. Cancer therapeutics is a large and competitive market with significant unmet needs.
Positioning
Kronos Bio focuses on specific targets within cancer, using a targeted approach to drug discovery. Their advantage lies in their expertise in transcription factor modulation.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Kronos Bio is targeting specific subsets of cancer patients, representing a significant portion of this overall market. Specific TAM for AML and MYC-driven cancers are also significant.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Experienced management team
- Focus on novel targets
- Pipeline of clinical-stage assets
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
- Dependence on successful development of pipeline products
Opportunities
- Potential to address unmet needs in cancer treatment
- Strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline through further drug discovery efforts
- Positive clinical trial data could lead to rapid value appreciation
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- BMY
- MRTX
- GILD
Competitive Landscape
Kronos Bio faces significant competition from established pharmaceutical companies with greater resources. Their advantage lies in their innovative approach to drug discovery and targeting of specific pathways.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by progress in clinical trials. Significant increases in value are tied to positive data releases.
Future Projections: Future growth depends on the successful development and commercialization of their pipeline products. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Focusing on key clinical trials for Entospletinib and KB0742 and seeking potential partnerships.
Summary
Kronos Bio is a clinical-stage company focusing on cancer therapeutics, especially those targeting AML and MYC-driven tumors. The company's strengths lie in its innovative technology and experienced team. However, it faces risks common to the biopharmaceutical industry, including clinical trial failures. Positive clinical data is crucial for future growth.
Similar Companies
- MRTX
- ARWR
- VIR
- CRSP
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biopharmaceutical companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kronos Bio Inc
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2020-10-09 | Interim CEO, CFO, COO & President Dr. Deborah A. Knobelman Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://www.kronosbio.com |
Full time employees 10 | Website https://www.kronosbio.com | ||
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.